Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | KAT8 | Q9H7Z6 | 7/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CCR9 | P51686 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1788483 | 1.00 | MAPT (0.34) | MAPTMAPK1SMN1; SMN2L3MBTL1PDPK1 | |
| SCHEMBL1788485 | 1.00 | MAPT (0.34) | MAPTMAPK1SMN1; SMN2L3MBTL1PDPK1 | |
| SCHEMBL12613388 | 0.86 | MAPT (0.35) | MAPTMAPK1SMN1; SMN2L3MBTL1PDPK1 | |
| SCHEMBL1786841 | 0.83 | MAPT (0.35) | MAPTMAPK1SMN1; SMN2L3MBTL1PDPK1 | |
| SCHEMBL1786843 | 0.83 | MAPT (0.35) | MAPTMAPK1SMN1; SMN2L3MBTL1PDPK1 | |
| SCHEMBL1786838 | 0.83 | MAPT (0.35) | MAPTMAPK1SMN1; SMN2L3MBTL1PDPK1 | |
| SCHEMBL1081047 | 0.83 | EP300 (0.35) | KAT8 | |
| SCHEMBL1081043 | 0.83 | EP300 (0.35) | KAT8 | |
| SCHEMBL1081046 | 0.83 | EP300 (0.35) | KAT8 | |
| SCHEMBL1787197 | 0.80 | MAPT (0.33) | MAPTMAPK1SMN1; SMN2L3MBTL1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124634-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | PONIARD PHARMACEUTICALS, INC. | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124634-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | PARK7, BDNF, BACE1 | MAPT 26/4885MAPK1 1938/4885SMN1; SMN2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.